Arcturus Therapeutics(ARCT) - 2023 Q4 - Annual Results

ArcturusTherapeuticsAnnouncesFourthQuarterandFiscalYear2023FinancialUpdateandPipeline Progress Kostaive® anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-810 remains on track for Phase 2 interim data by the end of Q2 ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea Cash runway extended to Q1 2027 Investor conference call at 4:30 p.m. E ...